NASDAQ$XERS
Xeris Biopharma Holdings Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Achieved record net product revenue and raised year-end cash balance guidance.
Xeris Biopharma reported a strong third quarter with record net product revenue of $29.6 million, a 17% increase from Q2 2022 and a 31% increase from the same period last year on a pro forma basis. The company also raised its year-end cash balance guidance to $110-$120 million and reaffirmed its full-year total net product revenue guidance to $105M-$110M.
- Record net product revenue of $29.6 million, up 17% from Q2 2022.
- Gvoke net revenue increased by 24% compared to Q3 2021.
- Keveyis net revenue increased by 17% compared to Q3 2021 on a pro forma basis.
- Raised year-end cash balance guidance to $110-$120 million.
Headline financials
Revenue & EPS history
Xeris Biopharma · Revenue · Quarterly
$29.7M
Revenue by segment
Xeris Biopharma · $29.6M total across 3 segments · Q3 2022
- Gvoke$13.7M+24.2%46.2%
- Keveyis$13.4M+16.3%45.2%
- Recorlev$2.52M—8.5%
Forward guidance
The company has tightened full-year total net product revenue guidance to $105M-$110M and raised 2022 year-end cash balance guidance from $90M-$110M to $110M-$120M. Remains on track to achieve $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023
Tailwinds
- Tightened full-year total net product revenue guidance to $105M-$110M
- Raised 2022 year-end cash balance guidance from $90M-$110M to $110M-$120M
- Remains on track to achieve $50M in synergies by year-end 2022
- Remains on track to achieve cash flow breakeven by year-end 2023
- Expect to build upon 2022 momentum and continue creating shareholder value through continued revenue growth
Headwinds
- No specific negatives provided in the earnings report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+4.5%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+33.5%
Q1 2020
Best reaction
-21.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | -1.9% | -3.1% | |
| Q4 2025 | -2.0% | -5.1% | -1.3% | |
| Q3 2025 | -21.8% | -24.6% | -34.0% | |
| Q1 2025 | +15.2% | +9.4% | +2.2% | |
| Q4 2024 | +9.5% | +16.4% | +17.0% | |
| Q3 2024 | -2.4% | -6.2% | +9.2% | |
| Q2 2024 | +8.9% | +19.2% | +17.8% | |
| Q1 2024 | -4.9% | +2.7% | +25.9% | |
| Q4 2023 | -20.8% | -26.9% | -33.8% | |
| Q3 2023 | -14.9% | -21.2% | +2.5% | |
| Q2 2023 | -5.6% | -8.4% | -14.1% | |
| Q1 2023 | +22.1% | +20.8% | +22.9% | |
| Q4 2022 | -18.3% | -20.9% | +23.5% | |
| Q3 2022 | +0.0% | -5.3% | -3.3% | |
| Q2 2022 | +7.1% | +11.2% | +7.1% | |
| Q1 2022 | -15.1% | +23.5% | +5.6% | |
| Q4 2021 | +9.3% | +8.1% | -4.5% | |
| Q3 2021 | +6.1% | +26.5% | +13.3% | |
| Q2 2021 | -18.9% | -18.9% | -4.6% | |
| Q1 2021 | +3.3% | +7.8% | +18.6% | |
| Q4 2020 | -8.1% | +1.9% | -9.7% | |
| Q3 2020 | -0.9% | -3.1% | -26.1% | |
| Q2 2020 | -1.8% | +25.1% | +43.6% | |
| Q1 2020 | +33.5% | +62.8% | +100.0% | |
| Q4 2019 | -10.9% | -21.9% | -2.5% | |
| Q3 2019 | -10.1% | -8.2% | -1.9% | |
| Q2 2019 | -1.4% | +5.9% | +5.9% | |
| Q1 2019 | +13.3% | +13.3% | -22.8% | |
| Q4 2018 | -5.8% | -10.4% | -6.2% | |
| Q3 2018 | +5.8% | -9.3% | -13.0% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro